AngioDynamics announced that the FDA has cleared the AlphaVac F1885 System for the treatment of pulmonary embolism, or PE. PE affects around 900,000 people in the United States every year and is the third leading cause of cardiovascular mortality in the nation. The expanded FDA indication allows for the utilization of the AlphaVac F1885 System for the treatment of PE, which broadens the applicability of the AlphaVac F1885 System in the non-surgical removal of thrombi or emboli from the venous vasculature. The indication expands treatment options for patients with PE, reducing thrombus burden and improving right ventricular function.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANGO:
- ANGO Earnings this Week: How Will it Perform?
- AngioDynamics settles litigation with Becton Dickinson
- Options Volatility and Implied Earnings Moves This Week, April 01 – April 05, 2024
- AngioDynamics price target raised to $18 from $17 at Canaccord
- AngioDynamics price target lowered to $14 from $18 at H.C. Wainwright